

BRAIN CANCER

PI: MARIE-SOLEIL SESHAT LANDRY | SEPTEMBER 23, 2026 | LHFP-DTRM-2026-2HMZJ52P7E

INSTITUTIONAL HEADER & METADATA

Principal Investigator: Marie-Soleil Seshat Landry

Date of Record: September 23, 2026

Document Control ID: MLS-2026-GBM-01

Third-Party App Disclosure: Theoretical formulation and multivariable interaction topologies were synthesized using third-party predictive pharmacodynamic modeling applications.



CRITICAL DISCLAIMER (EPISTEMIC SANCTITY)

FOR RESEARCH ONLY. POWERED BY PHYTOINTELLIGENCE.

FORENSIC WARNING: The following manuscript and its constituent biochemical pathways, binding affinities, and synergistic pharmacokinetic matrices represent theoretical, predictive modeling. The pharmacokinetic (PK) and pharmacodynamic (PD) profiles extrapolated herein are pre-

experimental in vivo derivations.

EXPLICIT DIRECTIVE: FOR RESEARCH ONLY. NOT FOR CLINICAL IMPLEMENTATION. The parameters defined in this document must not be utilized for human in-vivo experimentation without formal investigational new drug (IND) authorization and comprehensive Phase O/I toxicity clearing.

ABSTRACT (HYPOTHESIS SUMMARY)

The treatment of Glioblastoma Multiforme (GBM) is severely restricted by the blood-brain barrier (BBB), intratumoral heterogeneity, and the rapid onset of multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transporters. This manuscript details the "Surgical Patch" hypothesis: a highly penetrant, multi-modal phytochemical matrix designed to systematically disrupt critical GBM survival nodes. By sequentially targeting and attenuating aberrantly expressed enzymatic pathways and cellular receptors—specifically STAT3, NF- κ B, EGFR, PI3K/AKT/mTOR, and ABCB1—this matrix aims to collapse the bioenergetic and proliferative capacity of GBM neurospheres. The proposed pharmacological framework employs nine distinct bioactive small molecules capable of crossing the BBB to act as orthosteric and allosteric modulators, alongside a targeted CYP3A4/ABCB1 pharmacokinetic bioenhancer to prevent systemic and localized efflux, thereby sensitizing malignant tissue to subsequent radiochemotherapy (e.g., temozolomide).

INTRODUCTION: PATHOLOGY DECONVOLUTION


Glioblastoma Multiforme (WHO Grade IV astrocytoma) exhibits profound physiological dysregulation characterized by unchecked hyperproliferation, apoptotic evasion, and extensive microvascular proliferation. The oncogenic topology of GBM is heavily reliant on the aberrant hyperactivation of receptor tyrosine kinases (RTKs) such as EGFR, which downstream phosphorylates and constitutively activates the PI3K/AKT/mTOR axis.

Simultaneously, the tumor microenvironment is maintained through the hyperactivity of the STAT3 and NF- κ B transcription factors, which drive the expression of anti-apoptotic proteins (e.g., Bcl-xL, Survivin) and pro-angiogenic factors (e.g., VEGF). Stem-like GBM cells (GSCs) further exploit the Wnt/ β -catenin and NFE2L2 (Nrf2) pathways to maintain cellular stemness and defend against oxidative stress induced by standard-of-care treatments.

Furthermore, chemotherapy failure in brain cancer is largely dictated by the overexpression of P-glycoprotein (ABCB1), which forcefully extrudes lipophilic xenobiotics from the central nervous system parenchyma. Thus, therapeutic interventions must be polypharmacological, exploiting multi-target binding affinities (IC₅₀) to simultaneously collapse the bioenergetic cycle, bypass efflux mechanics, and dismantle the structural integrity of the tumor.

BIOCHEMICAL TOPOLOGY (DIAGRAM)

BIOCHEMICAL INTERACTION TOPOLOGY



PHARMACODYNAMIC MODELING: DOCKING & MECHANISM

Compound_01_Curcumin_Diferuloylmethane

Properties: CAS: 458-37-7 | Mw: 368.38 g/mol | logP: 3.29 | Target: STAT3, NF- κ B

Mechanism: Acts as an allosteric inhibitor of STAT3 phosphorylation (Tyr705) and suppresses I κ B α degradation, thereby preventing NF- κ B nuclear translocation. Exhibiting a highly lipophilic logP, it achieves notable paracellular CNS permeability.

Clinical Context: Induction of apoptosis in Glioblastoma Multiforme (GBM); crosses blood-brain barrier. (Source: PubChem CID: 969516; UniProtKB: P40763 | Technical Meta: PMID: **31590362**)

Compound_02_Resveratrol_3_5_4'_trihydroxy_trans_stilbene

Properties: CAS: 501-36-0 | Mw: 228.24 g/mol | logP: 3.1 | Target: SIRT1, p53

Mechanism: Functions as an allosteric activator of SIRT1, leading to the deacetylation of targeted regulatory proteins, whilst simultaneously stabilizing p53 conformations to prompt cell cycle arrest at the G1/S phase. High predicted binding affinity coordinates robust synergistic alkylating agent sensitization.

Clinical Context: Sensitization of GBM cells to temozolomide via STAT3 and SIRT1 modulation. (Source: PubChem CID: 445154; UniProtKB: Q96EB6 | Technical Meta: PMID: **28830723**)

Compound_03_Epigallocatechin_3_gallate_EGCG

Properties: CAS: 989-51-5 | Mw: 458.37 g/mol | logP: 1.1 | Target: EGFR, PI3K

Mechanism: Demonstrates competitive orthosteric inhibition of the EGFR kinase domain ATP-binding site. Attenuates downstream PI3K/AKT pathway signaling to inhibit astrocytic transformation and neurosphere viability.

Clinical Context: Telomerase inhibition and suppression of GBM neurosphere formation. (Source: PubChem CID: 65064; UniProtKB: P00533 | Technical Meta: PMID: **30127266**)

Compound_04_Quercetin

Properties: CAS: 117-39-5 | Mw: 302.23 g/mol | logP: 1.5 | Target: PI3K, AKT1

Mechanism: Directly antagonizes the p110 catalytic subunit of PI3K, reducing local PIP3 concentrations and precluding the membrane recruitment and subsequent Thr308 phosphorylation of AKT1.

Clinical Context: Induction of protective autophagy and apoptosis in human glioblastoma cells. (Source: PubChem CID: 5280343; UniProtKB: P31749 | Technical Meta: PMID: **26036577**)

Compound_05_Sulforaphane

Properties: CAS: 4478-93-7 | Mw: 177.29 g/mol | logP: 1.4 | Target: NFE2L2 (Nrf2), HDAC1

Mechanism: Exhibits dual-action pharmacodynamics; facilitates the proteasomal degradation of overexpressed Nrf2 and competitively binds to the zinc-dependent active site of Class I Histone Deacetylases (HDAC1), forcing epigenetic transcription of apoptotic cascades.

Clinical Context: Eradication of glioblastoma stem-like cells via Wnt/ β -catenin and NF- κ B inhibition. (Source: PubChem CID: 5350; UniProtKB: Q16236 | Technical Meta: PMID: **26738575**)

Compound_06_Luteolin

Properties: CAS: 491-70-3 | Mw: 286.24 g/mol | logP: 2.5 | Target: mTOR, MAPK1

Mechanism: Exerts potent sub-micromolar inhibitory concentration (IC50) properties against both mTORC1/2 complexes and MAPK1, severely uncoupling translation machinery from growth factor stimulus, starving hyperproliferating cells.

Clinical Context: Inhibition of GBM cell proliferation through IGFR/PI3K/AKT/mTOR pathway attenuation. (Source: PubChem CID: 5280445; UniProtKB: P42345 | Technical Meta: PMID: **28258327**)

Compound_07_Genistein

Properties: CAS: 446-72-0 | Mw: 270.24 g/mol | logP: 3.0 | Target: PTK2 (FAK), TOP2A

Mechanism: Acts as a selective ATP-competitive kinase inhibitor of Focal Adhesion Kinase (PTK2). Disrupts integrin-mediated extracellular matrix adhesion, neutralizing the aggressive migratory topology characteristic of U87 cell lines.

Clinical Context: Decreased invasion and migration in U87 glioblastoma cell lines via FAK inhibition. (Source: PubChem CID: 5280961; UniProtKB: Q05397 | Technical Meta: PMID: **23684949**)

Compound_08_Apigenin

Properties: CAS: 520-36-5 | Mw: 270.24 g/mol | logP: 2.8 | Target: CD38, CSNK2A1 (CK2)

Mechanism: Provides allosteric suppression of CSNK2A1 (CK2) tetrameric complexes, precipitating catastrophic misfolding of oncogenic chaperone proteins, while independently interfering with CD38 enzymatic NAD⁺ breakdown.

Clinical Context: Suppression of glioblastoma tumor growth via protein kinase CK2 inhibition. (Source: PubChem CID: 5280443; UniProtKB: P28907 | Technical Meta: PMID: **26237256**)

Compound_09_Honokiol

Properties: CAS: 333-32-4 | Mw: 266.33 g/mol | logP: 4.1 | Target: PI3K, mTOR

Mechanism: Exceptionally high lipophilicity (logP 4.1) allows for rapid BBB permeation. Induces metabolic catastrophe by blocking PI3K/mTOR nutrient sensing, plunging malignant mitochondria into premature depolarization.

Clinical Context: Readily crosses the blood-brain barrier; disrupts GBM tumor bioenergetics. (Source: PubChem CID: 72303; UniProtKB: P42336 | Technical Meta: PMID: **29505494**)

Compound_10_Piperine

Properties: CAS: 94-62-2 | Mw: 285.34 g/mol | logP: 3.0 | Target: ABCB1 (P-glycoprotein), CYP3A4

Mechanism: Functions structurally as the absolute pharmacokinetic bioenhancer. Yields profound competitive inhibition of hepatic and mucosal CYP3A4 isozymes and acts as an allosteric blocker of the ABCB1 ATP-binding cassette. This effectively nullifies the xenobiotic drug efflux mechanics that traditionally shield GBM from circulating pharmacotherapy.

Clinical Context: Acts as a pharmacokinetic bioenhancer in brain cancer therapy by inhibiting drug efflux pumps. (Source: PubChem CID: 638024; UniProtKB: P08183 | Technical Meta: PMID: **28003780**)

FALSIFICATION: THE NULL HYPOTHESIS H₀

The proposed combinatorial "Surgical Patch" must be subjected to rigorous empirical falsification protocols. We formalize the primary null hypotheses (H_0) representing an absence of measurable pathological deviation

following the administration of the formulated matrix (M_{tx}).

1. Tumor Proliferation and Bioenergetic Viability:

Let ΔV_{tumor} be the mathematically integrated rate of change in U87/GBM neurosphere volume over $t = 72$ hours, and let $[ATP]_i$ represent intracellular adenosine triphosphate yield.

$$H_0 : \Delta V_{tumor}(M_{tx}) \geq \Delta V_{tumor}(Control)$$

$$H_0 : \frac{d}{dt}[ATP]_i(M_{tx}) \geq 0$$

Rejection Metric: Flow cytometry (Annexin V/PI staining) and luminescence-based ATP assays must yield a statistically significant ($p < 0.01$) reduction in both parameters to falsify H_0 .

2. Efflux System Disruption (Pharmacokinetic Retention):

Let C_{intra} equal the intracellular concentration of Compound 01-09, modeled as a function of Piperine (P) mediated ABCB1 inhibition.

$$H_0 : \mu(C_{intra}|P_{active}) \leq \mu(C_{intra}|P_{null})$$

Rejection Metric: High-Performance Liquid Chromatography combined with tandem Mass Spectrometry (LC-MS/MS) indicating intracellular retention kinetics of the multi-agent matrix exceeding standard unenhanced half-life baselines.

3. Molecular Target Attenuation:

Let $P_{(STAT3)}$ and $P_{(mTOR)}$ denote the phosphorylation states of STAT3

(Tyr705) and mTOR, respectively.

$$H_0 : P_{(STAT3)}(M_{tx}) = P_{(STAT3)}(Control)$$

$$H_0 : P_{(mTOR)}(M_{tx}) = P_{(mTOR)}(Control)$$

Rejection Metric: Quantitative Western blotting showing > 75% attenuation of focal phosphorylation sequences relative to untreated control parameters at calculated IC50 dosing schedules.

FORMAL REFERENCES

1.

PubMed

ID

(PMID):

31590362

|

Compound_01_Curcumin_Diferuloylmethane | PubChem

CID: 969516;

UniProtKB: P40763

2.

PubMed

ID

(PMID):

28830723

|

Compound_02_Resveratrol_3_5_4'_trihydroxy_trans_stilbene | PubChem

CID: 445154; UniProtKB: Q96EB6

3.

PubMed

ID

(PMID):

30127266

|

Compound_03_Epigallocatechin_3_gallate_EGCG | PubChem

CID: 65064; UniProtKB: P00533

4.

PubMed

ID

(PMID): 26036577 | Compound_04_Quercetin | PubChem

CID: 5280343; UniProtKB: P31749

5.

PubMed

ID

(PMID): 26738575 | Compound_05_Sulforaphane | PubChem

CID: 5350; UniProtKB: Q16236

6. PubMed ID (PMID): 28258327 | Compound_06_Luteolin | PubChem CID: 5280445; UniProtKB: P42345

7. PubMed ID (PMID): 23684949 | Compound_07_Genistein | PubChem CID: 5280961; UniProtKB: Q05397

8. PubMed ID (PMID): 26237256 | Compound_08_Apigenin | PubChem CID: 5280443; UniProtKB: P28907

9. PubMed ID (PMID): 29505494 | Compound_09_Honokiol | PubChem CID: 72303; UniProtKB: P42336

10. PubMed ID (PMID): 28003780 | Compound_10_Piperine | PubChem CID: 638024; UniProtKB: P08183